Deva Holding AS traded at 61.60 this Wednesday March 25th, decreasing 0.05 or 0.08 percent since the previous trading session. Looking back, over the last four weeks, Deva Holding AS lost 12.75 percent. Over the last 12 months, its price rose by 3.79 percent. Looking ahead, we forecast Deva Holding AS to be priced at 59.32 by the end of this quarter and at 52.98 in one year, according to Trading Economics global macro models projections and analysts expectations.
Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Company’s product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.